Nigeria Introduces Long-Acting HIV Prevention Injection in Major Public Health Step. Read original
Nigeria has expanded its HIV prevention strategy with the introduction of a new long-acting injectable drug designed to protect people who are at risk of contracting the virus.
The Federal Ministry of Health and Social Welfare announced the arrival of Lenacapavir (LEN) Pre-Exposure Prophylaxis (PrEP), a long-acting injectable medication that offers sustained protection against HIV infection.
The initiative is being rolled out through the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP), the government agency responsible for coordinating the country’s response to HIV, viral hepatitis, and sexually transmitted infections.
Health officials say the new prevention option represents a significant milestone in Nigeria’s efforts to reduce new HIV infections and strengthen access to modern prevention tools.
Expanding HIV Prevention Choices
For years, HIV prevention in Nigeria has relied heavily on daily oral PrEP medication and other measures such as condom use and awareness campaigns. However, maintaining strict adherence to daily medication has remained a challenge for many people at risk.
The newly introduced injectable alternative is expected to address that gap.
Lenacapavir works by providing long-lasting protection through periodic injections, eliminating the need for daily pills. Experts believe this could significantly improve adherence among individuals who struggle to take medication consistently.
According to the Federal Ministry of Health and Social Welfare, expanding prevention choices allows individuals to select the method that best fits their lifestyle, ultimately improving the overall effectiveness of HIV prevention efforts across the country.
Why This Development Matters
Nigeria continues to carry one of the largest HIV burdens globally. Although significant progress has been made in testing, treatment, and prevention, thousands of new infections are still recorded each year.
Public health experts say introducing innovative prevention tools like long-acting injectable PrEP could help close persistent gaps in protection, particularly among vulnerable populations.
By making prevention easier and more convenient, the government hopes to reach more people who may otherwise avoid or discontinue preventive medication.
Strengthening Nigeria’s Fight Against HIV
The launch of Lenacapavir PrEP also reflects Nigeria’s broader commitment to strengthening its public health systems and aligning with global strategies aimed at ending HIV as a public health threat.
Authorities say the rollout will be accompanied by expanded education, testing services, and community outreach programmes to ensure that those who need the medication can access it safely and effectively.
Looking Ahead
Health officials believe the introduction of long-acting injectable HIV prevention could mark a turning point in Nigeria’s battle against the virus.
If widely adopted, the new medication could help reduce new infections, improve treatment adherence, and bring the country closer to its long-term goal of eliminating HIV as a major public health challenge.
For millions of Nigerians at risk, the development offers renewed hope that the fight against HIV is entering a new and more effective phase.